Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03493165
Expanded Access Status : Available
First Posted : April 10, 2018
Last Update Posted : July 2, 2021
Sponsor:
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio

Tracking Information
First Submitted Date April 2, 2018
First Posted Date April 10, 2018
Last Update Posted Date July 2, 2021
 
Descriptive Information
Brief Title Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
Official Title Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
Brief Summary Single patient treatment with everolimus.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Uterine Sarcoma
Intervention Drug: Everolimus
mTOR inhibitor
Other Name: Zortress, Afinitor, and Afinitor Disperz
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Eligibility Criteria Not Provided
Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years and older   (Adult, Older Adult)
Contacts
Contact: John Sarantopoulos, MD 210-450-1785 sarantopoulo@uthscsa.edu
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03493165
Other Study ID Numbers CTMS# 18-0020
Responsible Party The University of Texas Health Science Center at San Antonio
Study Sponsor The University of Texas Health Science Center at San Antonio
Collaborators Not Provided
Investigators Not Provided
PRS Account The University of Texas Health Science Center at San Antonio
Verification Date June 2021